Biosimilars in Bone Health Treatment

Osteoporosis is underdiagnosed and undertreated 1• Osteoporosis increases the risk of fractures, which are associated with pain, disability, and mortality 4,5• After a major osteoporotic fracture, the risk of a second fracture within one year is 2.7-fold higher than among the general population 6• 60-85% % of females >50 years of age with osteoporosis did not receive treatment in 2018 7 OSTEOPOROSIS:• Antiresorptive medications* are underused in patients with bone metastases 2• It is estimated that more than half of cancers develop bone metastases 8• Most (~68% %) of patients with skeletal metastasis experience pain, and many sustain fractures, 8 leading to significant deterioration in quality of life and worsened survival 2• Many (39% %) of patients with mCRPC did not receive bone health agents during follow-up 2 BONE METASTASIS:*Antiresorptive drugs include bisphosphonates, denosumab,